A Comprehensive Guide to Benralizumab Adverse Reactions: Prevention and Management

　　Benralizumab(brand name Fasenra),an anti-IL-5Rαmonoclonal antibody,demonstrates significant efficacy in severe eosinophilic asthma.While generally well-tolerated,clinicians and patients must be aware of potential adverse reactions to ensure safe use.

　　1.Common Adverse Reactions:Headache and Sore Throat

　　Clinical data indicates that headache and sore throat are the most frequently reported events,typically mild to moderate and transient,occurring early in treatment.Management recommendations:

　　●Headache:Recommend rest,hydration,and over-the-counter analgesics(e.g.,acetaminophen)if needed under medical supervision.

　　●Sore Throat:Increase fluid intake,use throat lozenges or saltwater gargles.Most cases resolve spontaneously without specific treatment.

　　2.Hypersensitivity Reactions and Injection Site Issues

　　As a biologic,Benralizumab carries a risk of hypersensitivity reactions,including rash,urticaria,itching,facial swelling,and rare anaphylaxis(difficulty breathing,hypotension).Response protocols:

　　1.Precaution:Monitor patients for 30 minutes post-first dose in a healthcare setting.

　　2.Mild Reactions:Antihistamines(e.g.,loratadine)or corticosteroids may be administered by the physician.

　　3.Severe Reactions:Immediately discontinue medication and initiate emergency protocols(e.g.,epinephrine).

　　Injection site reactions(pain,redness,bruising)are also common.Mitigation strategies:

　　●Rotate injection sites(thigh,abdomen,upper arm).

　　●Apply gentle pressure with a dry swab post-injection;avoid rubbing.

　　●Cold compress can减轻local inflammation.

　　3.Infection Risk:Focus on Parasite Prevention

　　By depleting eosinophils—key defenders against parasites like helminths—Benralizumab may increase parasitic infection risk.Clinical reports confirm this association.Key preventive measures:

　　1.Pre-treatment Screening:Assess parasite exposure risk(e.g.,in endemic areas);consider stool examinations if warranted.

　　2.Active Infection Management:Treat existing infections prior to initiating Benralizumab.

　　3.Ongoing Surveillance:If gastrointestinal symptoms(abdominal pain,diarrhea)emerge during therapy,temporarily suspend medication,treat infection,and reassess continuation once resolved.

　　4.Rare but Serious Reactions

　　Monitor for potentially severe events:

　　●Hepatic Dysfunction:Asymptomatic transaminase elevations occur rarely.Require regular liver function tests;withhold medication and institute hepatoprotective measures if significantly abnormal.

　　●Cardiovascular Events:Isolated reports of myocardial infarction/stroke have been documented,though causality remains unclear.Weigh risks carefully in patients with cardiovascular comorbidities.

　　Important:Seek immediate medical evaluation for unexplained fever,severe headache,worsening dyspnea,or new-onset rash during treatment.

　　Effective Benralizumab safety relies on collaborative risk assessment,vigilant monitoring,and prompt symptom recognition between healthcare providers and patients.